GWPH GW Pharmaceuticals plc Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

GWPH [NASD]

GW Pharmaceuticals plc

Healthcare | Drug Manufacturers - General | United Kingdom

statements

Index	-	P/E	-	EPS (ttm)	-1.79	Insider Own	1.12%	Shs Outstand	31.29M	Perf Week	-0.49%
Market Cap	3.02B	Forward P/E	49.15	EPS next Y	1.93	Insider Trans	-69.33%	Shs Float	30.83M	Perf Month	-3.55%
Income	-55.50M	PEG	-	EPS next Q	-0.84	Inst Own	88.80%	Short Float	16.07%	Perf Quarter	-26.21%
Sales	442.00M	P/S	6.84	EPS this Y	97.60%	Inst Trans	8.03%	Short Ratio	13.05	Perf Half Y	-10.25%
Book/sh	22.91	P/B	4.15	EPS next Y	192.30%	ROA	-6.40%	Target Price	-	Perf Year	-26.73%
Cash/sh	15.01	P/C	6.33	EPS next 5Y	-	ROE	-7.70%	52W Range	67.98 - 141.98	Perf YTD	-9.14%
Dividend	-	P/FCF	-	EPS past 5Y	19.00%	ROI	-15.90%	52W High	-33.09%	Beta	1.93
Dividend %	-	Quick Ratio	5.00	Sales past 5Y	59.60%	Gross Margin	92.10%	52W Low	39.75%	ATR	3.00
Employees	901	Current Ratio	5.80	Sales Q/Q	68.50%	Oper. Margin	-12.20%	RSI (14)	41.10	Volatility	2.83% 3.03%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	-111.10%	Profit Margin	-12.60%	Rel Volume	0.68	Prev Close	97.04
Shortable	Yes	LT Debt/Eq	0.02	Earnings	Nov 03 AMC	Payout	-	Avg Volume	379.71K	Price	95.00
Recom	1.80	SMA20	-1.58%	SMA50	-5.88%	SMA200	-14.02%	Volume	259,903	Change	-2.10%

Aug-25-20

Initiated

Raymond James

Mkt Perform

Aug-07-20

Reiterated

Needham

Buy

$190 → $180

Jul-15-20

Downgrade

Stifel

Buy → Hold

$150 → $140

Jun-30-20

Reiterated

Evercore ISI

Outperform

$250 → $275

Jun-01-20

Resumed

Oppenheimer

Outperform

$173 → $166

Apr-08-20

Initiated

Northland Capital

Outperform

$128

Mar-06-20

Initiated

Citigroup

Buy

$192

Oct-30-19

Initiated

H.C. Wainwright

Buy

$170

Oct-21-19

Initiated

Needham

Buy

$200

May-07-19

Upgrade

Oppenheimer

Perform → Outperform

May-07-19

Reiterated

Guggenheim

Buy

$186 → $222

May-07-19

Reiterated

Cantor Fitzgerald

Overweight

$196 → $229

Mar-18-19

Reiterated

Cantor Fitzgerald

Overweight

$193 → $196

Jan-02-19

Initiated

JP Morgan

Overweight

$134

Nov-05-18

Resumed

Piper Jaffray

Overweight

Sep-28-18

Reiterated

BofA/Merrill

Buy

$181 → $197

Sep-07-18

Resumed

Morgan Stanley

Overweight

Aug-15-18

Initiated

Stifel

Buy

$181

Aug-08-18

Reiterated

Cantor Fitzgerald

Overweight

$235 → $211

Apr-19-18

Reiterated

Cantor Fitzgerald

Overweight

$192 → $205

Oct-22-20 10:34AM	GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020 GlobeNewswire
Oct-21-20 08:00AM	Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community GlobeNewswire
Oct-19-20 10:39AM	Hedge Funds Are Getting Out Of GW Pharmaceuticals plc (GWPH) Insider Monkey
Oct-16-20 11:02AM	3 Marijuana Stocks to Buy With Decriminalization on the Table InvestorPlace
Oct-15-20 02:45PM	GW Pharmaceuticals Could Bottom Out Into Year-End TheStreet.com
Oct-12-20 09:50AM	New CBD Rules In Australia Bode Well For Overall Market, Observers Say Benzinga
Oct-10-20 10:45AM	What Type Of Returns Would GW Pharmaceuticals'(NASDAQ:GWPH) Shareholders Have Earned If They Purchased Their SharesYear Ago? Simply Wall St.
Sep-30-20 03:26PM	Top Marijuana Stocks on the NASDAQ for October 2020 Investopedia
Sep-23-20 08:05AM	The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma Benzinga
08:00AM	GW Pharmaceuticals: Buy the Dip? Motley Fool
03:54AM	GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy GlobeNewswire
Sep-15-20 07:52AM	GW Pharmaceuticals Has Been Basing but Needs More Development TheStreet.com
Sep-10-20 04:00PM	Greenwich Biosciences to Share Results of Cannabis Use Survey Conducted with the North American Research Committee on Multiple Sclerosis (NARCOMS) at Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020 GlobeNewswire
04:00PM	Greenwich Biosciences to Present Data on Safety and Efficacy of Nabiximols in Persons with Multiple Sclerosis-Associated Spasticity at the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020 GlobeNewswire
07:08AM	3 Cannabis Stocks to Avoid Like the Plague in September Motley Fool
07:00AM	GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors GlobeNewswire
Sep-03-20 06:30AM	Better Cannabis Stock: Charlotte's Web vs. GW Pharmaceuticals Motley Fool
Sep-02-20 01:24PM	Marijuana Medicine: Thrilling Time for Investors Zacks
Sep-01-20 07:00AM	GW Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Aug-29-20 06:41AM	Can GW Pharmaceuticals Stock Bounce Back? Motley Fool
Aug-26-20 12:38PM	Rock star Growth Puts GW Pharmaceuticals (NASDAQ:GWPH) In A Position To Use Debt Simply Wall St.
Aug-24-20 07:21AM	3 Cannabis Stocks Billionaires Were Buying in Q2 Motley Fool
Aug-16-20 10:47AM	2 Top Pharma Stocks to Buy in August Motley Fool
Aug-07-20 11:24AM	GW Pharma shares slide 12% after company swings to loss during pandemic MarketWatch -17.21%
07:34AM	The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs Benzinga
Aug-06-20 04:44PM	GW Pharmaceuticals: Q3 Earnings Insights Benzinga
04:00PM	GW Pharmaceuticals plc Reports Second Quarter 2020 Financial Results and Operational Progress GlobeNewswire
Aug-03-20 03:45PM	Why GW Pharmaceuticals Stock Is Up Today Motley Fool
03:36PM	GW Pharmaceuticals' Epidiolex Wins New FDA Approvals Motley Fool
02:05PM	GW Pharma's stock rallies after its cannabinoid drug gets a new FDA approval MarketWatch
01:01PM	Did Hedge Funds Make The Right Call On GW Pharmaceuticals plc (GWPH) ? Insider Monkey
07:00AM	FDA Approves EPIDIOLEX® (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex GlobeNewswire
01:29AM	GW Pharma Scores New FDA Approval For CBD Drug Epidiolex SmarterAnalyst
Aug-02-20 09:34AM	Should Investors Buy GW Pharma Stock Right Now? Motley Fool
Jul-30-20 11:53AM	Will Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings? Zacks
Jul-26-20 09:54AM	The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings Benzinga
08:10AM	2 Top Pot Stocks to Buy in a Recession Motley Fool
Jul-25-20 06:56AM	3 Biotech Stocks With Big Incoming Catalysts Motley Fool
Jul-23-20 07:00AM	GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Second Quarter Ending June 30th, 2020 and Host Conference Call on August 6th, 2020 GlobeNewswire
Jul-21-20 03:09PM	FDA releases guidelines for cannabis-related research, but CBD will have to wait MarketWatch
Jul-17-20 04:21PM	Better Buy: GW Pharmaceuticals vs. Corbus Pharmaceuticals Motley Fool
12:27PM	Doctors Ethan Russo And Dale Hunt Join Robert Clarke To Launch Cannabis IP-Licensing Firm Benzinga
09:05AM	Why Cannabis Stocks May See Better Days Investopedia
Jul-15-20 06:51PM	GW Pharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
08:22AM	GW Pharmaceuticals stock slips after Stifel analyst backs off long-standing bullish view MarketWatch
Jul-14-20 08:08AM	Could GW Pharmaceuticals Be a Millionaire-Maker Stock? Motley Fool +5.56%
Jul-13-20 07:21AM	The First Pot Stock to Hit $1 Billion in Annual Sales Will Be...? Motley Fool
Jul-12-20 09:34AM	Better Cannabis Play: GW Pharmaceuticals vs. Innovative Industrial Properties Motley Fool
08:24AM	Can Mixed Fundamentals Have A Negative Impact on GW Pharmaceuticals plc (NASDAQ:GWPH) Current Share Price Momentum? Simply Wall St.
Jul-11-20 07:48AM	Got $5,000? These 2 Market-Beating Pot Stocks Are Still Hot Buys Right Now Motley Fool
Jul-09-20 06:49AM	3 Marijuana Stock Winners in the First Half of 2020 That Are Still Great Picks Motley Fool
Jul-07-20 07:21AM	The 5 Best Pot Stocks in the First Half of 2020 Motley Fool
Jun-30-20 08:08AM	Is GW Pharmaceuticals Stock a Buy? Motley Fool
07:00AM	GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy GlobeNewswire
Jun-25-20 11:26AM	Zacks Market Edge Highlights: Canopy Growth, Aurora Cannabis, Hexo, GW Pharmaceuticals and Zynerba Zacks
Jun-24-20 01:00PM	Cannabis Companies Eyeing How Plant Could Help Autism Symptoms TheStreet.com
11:38AM	Is This a Buying Opportunity in the Marijuana Stocks? Zacks
08:07AM	The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact Benzinga
07:29AM	UK Relaxes Rules On GWPH Cannabis Drug Epidyolex; Analysts Bullish On Stocks Prospects SmarterAnalyst
Jun-23-20 07:01PM	GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug GlobeNewswire
Jun-18-20 03:48PM	Hedge Funds Arent Crazy About GW Pharmaceuticals plc (GWPH) Anymore Insider Monkey
02:57PM	Is it Time to Buy Cannabis Stocks & ETFs? Zacks
Jun-16-20 10:31AM	Why the Cannabis Sector May be Turning a New Leaf Investopedia
Jun-10-20 06:19AM	1 Cannabis Stock Beating the Market This Year Motley Fool
Jun-05-20 04:24PM	Marijuana Medicine: Thrilling Time for Investors Zacks
10:45AM	GW Pharmaceuticals Is Picking Up Steam in 2020 Motley Fool
Jun-04-20 04:00PM	GW Pharmaceuticals to Host Virtual Investor Event on Its Nabiximols U.S. Development Program and Market Opportunity GlobeNewswire
Jun-02-20 07:00AM	GW Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference GlobeNewswire
May-28-20 02:55PM	7 High-Risk Stocks For Market Gamblers Benzinga
May-24-20 12:25PM	3 Top Pharma Stocks to Buy Right Now Motley Fool
May-22-20 10:26AM	Cannabis Short Sellers Down $641M In May Benzinga
May-21-20 02:59PM	GW Pharmaceuticals Looks Like It Is Ending Its Downtrend TheStreet.com
07:56AM	Cramer Gives His Opinion On GW Pharma, Bed Bath & Beyond And More Benzinga
May-13-20 06:19AM	3 Safe Cannabis Stocks to Hold During the COVID-19 Pandemic Motley Fool
May-12-20 08:06AM	The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings Benzinga
07:02AM	How GW Pharmaceuticals Hit a Home Run in Q1 Motley Fool
01:54AM	GW Pharma Pops 9% After-Hours As Epidiolex Smokes Expectations SmarterAnalyst
01:01AM	GW Pharmaceuticals PLC (GWPH) Q1 2020 Earnings Call Transcript Motley Fool
May-11-20 06:23PM	Marijuana Stock GW Pharmaceuticals Delivers Rapid Growth In Q1 Motley Fool
05:12PM	Cannabis-Focused Biotech Surges After Seizure Drug Outsells Estimates Investor's Business Daily
04:09PM	GW Pharmaceuticals sells more of CBD-derived epilepsy drug than expected, stock rises MarketWatch
04:00PM	GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress GlobeNewswire
May-07-20 11:17AM	What's in Store for GW Pharmaceuticals (GWPH) in Q1 Earnings? Zacks
May-06-20 06:28AM	Is It Time to Get in on GW Pharmaceuticals While the Price Is Right? Motley Fool
May-01-20 07:00AM	GW Pharmaceuticals to Present at the Bank of America Healthcare Conference 2020 GlobeNewswire
Apr-28-20 10:33AM	Cannabis Stock Rally Puts Short Sellers In The Red For 2020 Benzinga
Apr-27-20 08:09AM	How Does Investing In GW Pharmaceuticals plc (NASDAQ:GWPH) Impact The Volatility Of Your Portfolio? Simply Wall St.
Apr-21-20 02:04PM	GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the First Quarter Ending March 31st, 2020 and Host Conference Call on May 11th, 2020 GlobeNewswire
08:05AM	Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors GlobeNewswire
Apr-07-20 11:11AM	DEA Deschedules Expidiolex; GW Pharma's CBD Epilepsy Treatment No Longer A Controlled Substance Benzinga +5.94%
Apr-06-20 09:00AM	GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance GlobeNewswire +5.84%
Apr-01-20 12:20PM	FDA Grants GW Pharmaceuticals Priority Review For Cannabidiol Drug In Seizure Condition Benzinga
Mar-31-20 07:00AM	GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX® (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis Complex GlobeNewswire
Mar-24-20 04:20PM	Why This Biotech Stock And Its CBD Oil Are Immune To Coronavirus Investor's Business Daily +9.00%
Mar-20-20 07:05AM	Does GW Pharmaceuticals plc's (NASDAQ:GWPH) CEO Pay Compare Well With Peers? Simply Wall St. -5.21%
Mar-13-20 07:00AM	GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC) GlobeNewswire +8.88%
Mar-06-20 03:24PM	Medical Marijuana Investors: The Floodgates Are Opening Zacks
Mar-02-20 01:23PM	The Week In Cannabis: A Bunch Of Earnings And Policy Moves Around The World Benzinga
11:14AM	JAMA Neurology Publishes Results from Positive Phase 3 Trial of EPIDIOLEX® (cannabidiol) oral solution in Children with Seizures Associated with Dravet Syndrome GlobeNewswire
Feb-26-20 04:20PM	Why A CBD-Oil Seizure Drug Will Make Or Break This Biotech Stock Investor's Business Daily -8.59%

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Snyder Douglas B.	Chief Legal Officer	Sep 30	Sale	8.13	14,400	117,072	26,904	Oct 02 04:40 PM
Snyder Douglas B.	Chief Legal Officer	Aug 11	Sale	9.40	24,000	225,600	41,304	Aug 12 08:06 PM
Snyder Douglas B.	Chief Legal Officer	Aug 10	Option Exercise	0.00	131,544	171	122,364	Aug 12 08:06 PM
Knappertz Volker	Chief Medical Officer	Aug 04	Sale	11.11	6,000	66,660	47,940	Aug 06 08:01 PM
Knappertz Volker	Chief Medical Officer	Jul 20	Sale	11.42	6,000	68,520	53,940	Jul 22 08:00 PM
Snyder Douglas B.	Chief Legal Officer	Jul 06	Sale	10.50	9,804	102,942	0	Jul 08 08:00 PM
Knappertz Volker	Chief Medical Officer	Jun 17	Sale	10.35	18,000	186,300	59,940	Jun 19 08:02 PM
Gover Justin D.	Chief Executive Officer	Jun 15	Option Exercise	0.00	4,164	5	458,129	Jun 17 08:00 PM
GUY GEOFFREY W DR	Executive Chairman	May 29	Sale	10.25	720,000	7,376,400	5,501,521	Jun 02 08:00 PM
Cline Darren S	U.S. Chief Commercial Officer	May 28	Option Exercise	0.00	7,356	9	7,356	May 29 08:00 PM
Knappertz Volker	Chief Medical Officer	May 18	Option Exercise	0.00	133,620	160	139,092	May 20 08:02 PM
Giacobello Scott M.	Chief Financial Officer	May 18	Option Exercise	0.00	116,604	140	140,742	May 20 08:01 PM
Giacobello Scott M.	Chief Financial Officer	Mar 13	Buy	6.80	7,200	48,960	88,224	Mar 17 06:07 PM
GUY GEOFFREY W DR	Executive Chairman	Mar 13	Sale	6.63	600,000	3,978,000	6,221,521	Mar 17 06:05 PM
Gover Justin D.	Chief Executive Officer	Mar 02	Option Exercise	0.00	47,844	62	599,369	Mar 04 06:01 PM
Snyder Douglas B.	Chief Legal Officer	Mar 02	Sale	8.32	2,568	21,366	67,296	Mar 04 06:03 PM
MACKEY CATHERINE J	Director	Mar 02	Sale	8.35	1,356	11,323	16,392	Mar 04 06:04 PM
Brown Cabot	Director	Mar 02	Sale	8.24	3,144	25,907	17,088	Mar 04 06:03 PM
Gover Justin D.	Chief Executive Officer	Mar 02	Sale	8.33	32,856	273,789	566,513	Mar 04 06:01 PM
Secor Alicia	Director	Mar 02	Sale	8.34	1,296	10,809	16,440	Mar 04 06:02 PM
Giacobello Scott M.	Chief Financial Officer	Mar 02	Sale	8.34	2,220	18,515	81,024	Mar 04 06:00 PM
Knappertz Volker	Chief Medical Officer	Mar 02	Sale	8.32	3,420	28,454	79,392	Mar 04 06:01 PM
Snyder Douglas B.	Chief Legal Officer	Feb 26	Sale	9.17	3,876	35,550	69,864	Feb 28 06:06 PM
Gover Justin D.	Chief Executive Officer	Feb 26	Sale	9.05	12,000	108,558	551,525	Feb 28 06:02 PM
Knappertz Volker	Chief Medical Officer	Feb 26	Sale	9.18	3,012	27,636	82,812	Feb 28 06:02 PM
Giacobello Scott M.	Chief Financial Officer	Feb 26	Sale	9.17	3,852	35,323	83,244	Feb 28 06:01 PM
Gover Justin D.	Chief Executive Officer	Feb 03	Option Exercise	0.00	202,224	263	765,749	Feb 05 05:00 PM
Gover Justin D.	Chief Executive Officer	Feb 03	Sale	9.62	202,224	1,944,678	563,525	Feb 05 05:00 PM
GUY GEOFFREY W DR	Executive Chairman	Jan 15	Sale	9.44	900,000	8,493,000	6,821,521	Jan 17 05:00 PM
MACKEY CATHERINE J	Director	Jan 03	Sale	8.54	1,536	13,117	17,748	Jan 07 05:00 PM
Secor Alicia	Director	Jan 03	Sale	8.53	1,536	13,102	17,736	Jan 07 05:01 PM
Brown Cabot	Director	Jan 03	Sale	8.58	3,576	30,682	20,232	Jan 07 05:01 PM
Gover Justin D.	Chief Executive Officer	Dec 17	Option Exercise	0.00	10,668	14	568,865	Dec 19 05:02 PM
Gover Justin D.	Chief Executive Officer	Dec 17	Sale	9.17	5,340	48,968	563,525	Dec 19 05:02 PM
GUY GEOFFREY W DR	Executive Chairman	Nov 11	Sale	9.33	420,000	3,918,600	7,721,521	Nov 13 05:00 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience